Comparisons

How to Choose the Right GLP-1 Medication

GLP-1 Companion · 9 min read

The GLP-1 medication class now includes multiple approved agents across several manufacturers. For patients and clinicians, selecting the most appropriate drug for a given individual requires systematically working through clinical, logistical, and economic factors. This article provides a structured framework for making that decision.

Step 1: Clarify Your Primary Diagnosis

Your diagnosis is the first filter that shapes which GLP-1 medications are appropriate and how insurance will classify coverage.

• Type 2 diabetes only: Ozempic (semaglutide), Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Victoza or generic liraglutide 1.8 mg, Trulicity (dulaglutide), Byetta/Bydureon (exenatide) are all FDA-approved options
• Obesity only (BMI ≥30 or ≥27 with comorbidity, no diabetes): Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), Saxenda or generic liraglutide 3.0 mg
• Both T2D and obesity: Any of the above options may be appropriate; tirzepatide (Mounjaro or Zepbound depending on your coverage) is particularly favorable given its efficacy in both conditions
• Cardiovascular risk reduction alongside T2D: Ozempic (semaglutide) has FDA approval for CV event reduction in T2D; Wegovy has SELECT trial evidence for CV benefit in obesity without T2D

Step 2: Assess Your BMI and Comorbidities

BMI determines eligibility for obesity-specific approvals, while specific comorbidities may influence which agent is medically preferred.

• BMI ≥30 or ≥27 with comorbidity: Qualifies for all FDA-approved obesity GLP-1 treatments
• Established cardiovascular disease with T2D: Ozempic's CV indication makes it particularly well-supported; Victoza also has the LEADER trial CV benefit data
• Obesity with established CVD (no T2D): Wegovy has the SELECT trial data showing 20% reduction in major CV events; this is a significant clinical differentiator
• Obstructive sleep apnea with obesity: Tirzepatide (Zepbound) received an FDA approval expansion for sleep apnea reduction in 2024, the first drug approved for this indication alongside weight management
• Non-alcoholic steatohepatitis (NASH/MASH): Semaglutide has demonstrated benefit in early NASH data; specialty consultation is warranted
• Polycystic ovary syndrome (PCOS): GLP-1 medications improve insulin sensitivity and weight, making them frequently used in PCOS management, though off-label for this indication
• Chronic kidney disease: GLP-1 medications are generally well-tolerated; note that dehydration from GI side effects can transiently worsen kidney function

Step 3: Evaluate Insurance Coverage and Formulary

Insurance coverage is often the single most determinative factor in which GLP-1 a patient actually receives, regardless of clinical preference.

• Commercial insurance for T2D: Ozempic and Mounjaro are broadly covered as diabetes drugs; Rybelsus and Victoza have wider formulary access as older agents
• Commercial insurance for obesity: Coverage for Wegovy and Zepbound has expanded significantly, but many plans still require prior authorization with documented BMI, comorbidities, and prior lifestyle intervention attempts
• Medicare: Historically restricted from covering obesity-only drugs; 2026 changes are expanding coverage under the LIFE Act provisions, but implementation varies by plan and timing
• Medicaid: Highly variable by state; some states cover liraglutide for obesity but not semaglutide or tirzepatide; others have limited GLP-1 coverage entirely
• Employer self-insured plans: Increasingly adopting GLP-1 coverage for obesity with specific criteria; check your benefits portal for current formulary

Step 4: Understand Prior Authorization Requirements

Prior authorization (PA) is required by most insurance plans for GLP-1 obesity medications and many diabetes agents. Understanding the typical criteria helps both patients and prescribers prepare documentation in advance.

• BMI documentation: Typically requires recorded BMI from a recent clinical visit
• Comorbidity documentation: If BMI is 27-29, a documented comorbidity (hypertension, sleep apnea, dyslipidemia, T2D, etc.) is required for most plans
• Prior lifestyle intervention: Many plans require documentation of a structured diet and exercise program attempted for at least 6 months
• Step therapy: Some plans require trial of a less expensive agent first (e.g., metformin for diabetes, or phentermine/topiramate for obesity) before approving GLP-1s
• Diabetes-specific criteria: If prescribing for T2D, many plans require HbA1c above a threshold (often 7.5% or higher) and inadequate control on metformin

Step 5: Consider Administration Preference and Feasibility

• Once-weekly injection: Wegovy, Zepbound, Ozempic, Mounjaro — preferred by most patients for convenience
• Daily injection: Saxenda/generic liraglutide — higher injection burden but may suit patients who prefer daily routine reinforcement
• Oral: Rybelsus (daily oral semaglutide for T2D) — eliminates injection entirely but produces substantially lower weight loss and requires strict morning administration protocol
• Needle aversion: Consider Rybelsus for T2D patients who cannot tolerate injections; accept the trade-off in efficacy
• Travel considerations: Weekly injections require fewer supplies for travelers; pen storage (refrigerated until first use, then up to 56 days at room temperature for most products) should be factored in

GLP-1 Options for Type 2 Diabetes: Clinical Hierarchy

For patients with type 2 diabetes, major clinical guidelines (ADA, AACE, ESC) as of 2025-2026 generally recommend the following hierarchy based on clinical priorities:

1. Established cardiovascular disease: GLP-1 RA with proven CV benefit preferred — semaglutide (Ozempic) or liraglutide (Victoza)
2. Obesity-predominant T2D: Tirzepatide (Mounjaro) or semaglutide (Ozempic 2.0 mg) for maximum weight + glycemic benefit
3. Heart failure: SGLT2 inhibitors are often preferred first, but GLP-1 agents are not contraindicated
4. Chronic kidney disease: Both semaglutide and liraglutide have renal outcome data; consult nephrology for advanced CKD
5. Cost-sensitive T2D: Older GLP-1 agents (exenatide, dulaglutide) or generic liraglutide may be preferable; oral semaglutide is mid-range cost

GLP-1 Options for Obesity: Clinical Hierarchy

For patients with obesity as the primary indication (without T2D), the clinical hierarchy in 2026 is more straightforward given fewer approved options:

1. Maximum weight loss goal, good insurance coverage: Tirzepatide (Zepbound) 15 mg — highest average weight loss (~20%)
2. Obesity with established cardiovascular disease: Semaglutide (Wegovy) — SELECT trial CV event reduction data is a significant advantage
3. Obesity with sleep apnea: Tirzepatide (Zepbound) — only GLP-1 agent with FDA approval for sleep apnea reduction
4. Cost-sensitive without commercial insurance: Generic liraglutide 3.0 mg — most affordable approved option
5. Adolescents 12+: Both Saxenda/liraglutide and Wegovy are FDA-approved in this age group; consult a pediatric endocrinologist

When to Involve a Specialist

Many patients are appropriately managed on GLP-1 therapy by their primary care provider. However, specialist involvement adds value in certain situations:

• Endocrinologist: Complex T2D with multiple medications, suspected MEN2 or thyroid conditions, poor response to standard agents, significant hyperglycemia requiring intensive management
• Obesity medicine specialist: BMI >45, prior bariatric surgery, complex medication combinations, failure on multiple GLP-1 agents, eating disorder history
• Cardiologist: Established CVD when initiating GLP-1 therapy, significant arrhythmias, recent MI or stroke
• Gastroenterologist: Significant GI side effects not resolving, prior pancreatitis history, inflammatory bowel disease
• Pediatric endocrinologist: Adolescent patients with obesity, T2D, or complex metabolic conditions

Side Effect Tolerance as a Selection Factor

For patients who have previously tried a GLP-1 medication and discontinued due to side effects, this history should inform the next choice. Some clinically useful patterns:

• Stopped semaglutide due to GI intolerance: Consider tirzepatide — SURMOUNT-5 showed lower discontinuation rates for tirzepatide vs semaglutide in a head-to-head trial
• Stopped tirzepatide due to constipation: Semaglutide may produce less constipation in some patients
• Stopped weekly injections due to injection anxiety: Consider Rybelsus (oral, T2D only) or explore pre-injection desensitization strategies
• Preferred daily routine of Saxenda but wanted more efficacy: Weekly semaglutide (Wegovy) or tirzepatide (Zepbound) now available with greater efficacy

The "right" GLP-1 medication is not determined by clinical trial averages alone. It is the agent that is appropriate for your diagnosis, accessible through your insurance, affordable within your budget, compatible with your lifestyle, and that you can tolerate and sustain long-term.

The Bottom Line

Choosing a GLP-1 medication is a multidimensional decision that involves clinical appropriateness, insurance coverage, cost, administration preference, and individual tolerability. No single agent is universally best. Use this framework to organize your thinking before your appointment, and engage in a detailed conversation with your healthcare provider to identify the optimal starting point for your specific situation.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.